The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

References

• Bolden J E, Peart M J, Johnstone R W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784
   PubMed Web of Science ®Google Scholar
• Bhalla K N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23: 3971–3993
   PubMed Web of Science ®Google Scholar
• Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince H M. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev Anticancer Ther 2007; 7: 1439–1449
   PubMed Web of Science ®Google Scholar
• Richon V M, Sandhoff T W, Rifkind R A, Marks P A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014–10019
   PubMed Web of Science ®Google Scholar
• Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007; 7: 583–598
   PubMed Web of Science ®Google Scholar
• Zhang K, Dent S Y. Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem 2005; 96: 1137–1148
   PubMed Web of Science ®Google Scholar
• Rasheed W K, Johnstone R W, Prince H M. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007; 16: 659–678
   PubMed Web of Science ®Google Scholar
• Khan S B, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004; 125: 156–161
   PubMed Web of Science ®Google Scholar
• Lavelle D, Chen Y H, Hankewych M, DeSimone J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001; 68: 170–178
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Richardson P G, McMullan C, Poulaki V, Fanourakis G, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055–4062
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Tai Y T, Atadja P, Remiszewski S, Hideshima T, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102: 2615–2622
   PubMed Web of Science ®Google Scholar
• Maiso P, Carvajal-Vergara X, Ocio E M, Lopez-Perez R, Mateo G, Gutierrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781–5789
   PubMed Web of Science ®Google Scholar
• Piekarz R L, Frye R, Turner M, Wright J, Allen S, Kirschbaum M H, et al. Phase II trial of Romidepsin, FK228, in cutaneous and peripheral T-Cell lymphoma: clinical activity and molecular markers. Blood (Suppl.) 2006; 108: 2479
   Google Scholar
• Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49: 502–507
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, DiLiberto M, Cho H J, Gelbshtein U Y, Jayabalan D S, et al. Multicenter phase II trial of the histone deacetylase inhibitor depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). Blood (Suppl.) 2005; 106: 2574
   Google Scholar
• Golay J, Cuppini L, Leoni F, Mico C, Barbui V, Domenghini M, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007; 21: 1892–1900
   PubMed Web of Science ®Google Scholar
• Galli M, Salmoiraghi S, Golay J, Gozzini A, Bosi A, Crippa C, et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results. Blood (Suppl.) 2007; 110: 1175
   Google Scholar
• Spencer A, Prince M, DeAngelo D J, Fischer T, Bhalla K N, Giles F J, et al. Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. Blood (Suppl.) 2007; 110: 907
   Google Scholar
• Pei X Y, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839–3852
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T, Tai Y T, Hideshima T, Neri P, et al. Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441–3449
   PubMed Web of Science ®Google Scholar
• Sutheesophon K, Kobayashi Y, Takatoku M A, Ozawa K, Kano Y, Ishii H, et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol 2006; 115: 78–90
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kovacs J J, McLaurin A, Vance J M, Ito A, Yao T P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727–738
   PubMed Web of Science ®Google Scholar
• Prince M, Quach H, Neeson P, Keegan M, Copeman M, Peinert S, et al. Safety and efficacy of the combination of Bortezomib with the deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma: preliminary results of a phase I trial. Blood (Suppl.) 2007; 110: 1167
   Google Scholar
• Badros A, Philip S, Niesvizky R, Goloubeva O, Harris C, Zweibel J, et al. Phase I trial of suberoylanilide hydroxamic acid (SAHA)+bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts). Blood (Suppl.) 2007; 110: 1168
   PubMed Web of Science ®Google Scholar
• Weber D M, Jagannath S, Mazumder A, Sobecks R, Schiller G J, Gavino M, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma. Blood (Suppl.) 2007; 110: 1172
   Google Scholar
• Campbell R A, Sanchez E, Steinberg J, Share M, Wang J, Li M, et al. The novel potent pan-deacetylase (DAC) inhibitor, panobinostat (LBH589), markedly enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Blood (Suppl.) 2007; 110: 2520
   PubMed Web of Science ®Google Scholar
• Ocio E M, Vilanova D, San-Segundo L, Maiso P, Garayoa M, Atadja P, et al. Triple combinations of the HDAC inhibitor panobinostat (LBH589) + dexamethasone with either lenalidomide or bortezomib are highly effective in a multiple myeloma mouse model. Blood (Suppl.) 2007; 110: 1514
   Google Scholar